Summary | |
---|---|
Symbol | MYL9 |
Name | myosin, light chain 9, regulatory |
Aliases | MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | - |
Domain |
PF13405 EF-hand domain PF13833 EF-hand domain pair |
Function |
Myosin regulatory subunit that plays an important role in regulation of both smooth muscle and nonmuscle cell contractile activity via its phosphorylation. Implicated in cytokinesis, receptor capping, and cell locomotion. |
Biological Process |
GO:0003012 muscle system process GO:0006936 muscle contraction GO:0006937 regulation of muscle contraction GO:0007596 blood coagulation GO:0007599 hemostasis GO:0030168 platelet activation GO:0034109 homotypic cell-cell adhesion GO:0044057 regulation of system process GO:0050817 coagulation GO:0050878 regulation of body fluid levels GO:0070527 platelet aggregation GO:0090257 regulation of muscle system process |
Molecular Function |
GO:0008307 structural constituent of muscle GO:0017022 myosin binding GO:0032036 myosin heavy chain binding |
Cellular Component |
GO:0001725 stress fiber GO:0005859 muscle myosin complex GO:0015629 actin cytoskeleton GO:0016459 myosin complex GO:0016460 myosin II complex GO:0030016 myofibril GO:0030017 sarcomere GO:0030018 Z disc GO:0031674 I band GO:0032432 actin filament bundle GO:0042641 actomyosin GO:0043292 contractile fiber GO:0044449 contractile fiber part GO:0097517 contractile actin filament bundle |
KEGG |
hsa04022 cGMP-PKG signaling pathway hsa04024 cAMP signaling pathway hsa04270 Vascular smooth muscle contraction hsa04510 Focal adhesion hsa04530 Tight junction hsa04670 Leukocyte transendothelial migration hsa04810 Regulation of actin cytoskeleton hsa04921 Oxytocin signaling pathway |
Reactome |
R-HSA-422475: Axon guidance R-HSA-1266738: Developmental Biology R-HSA-2682334: EPH-Ephrin signaling R-HSA-3928663: EPHA-mediated growth cone collapse R-HSA-397014: Muscle contraction R-HSA-195258: RHO GTPase Effectors R-HSA-5627117: RHO GTPases Activate ROCKs R-HSA-5625900: RHO GTPases activate CIT R-HSA-5627123: RHO GTPases activate PAKs R-HSA-5625740: RHO GTPases activate PKNs R-HSA-400685: Sema4D in semaphorin signaling R-HSA-416572: Sema4D induced cell migration and growth-cone collapse R-HSA-373755: Semaphorin interactions R-HSA-162582: Signal Transduction R-HSA-194315: Signaling by Rho GTPases R-HSA-445355: Smooth Muscle Contraction |
Summary | |
---|---|
Symbol | MYL9 |
Name | myosin, light chain 9, regulatory |
Aliases | MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between MYL9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | MYL9 |
Name | myosin, light chain 9, regulatory |
Aliases | MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of MYL9 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | MYL9 |
Name | myosin, light chain 9, regulatory |
Aliases | MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of MYL9 in various data sets.
|
Points in the above scatter plot represent the mutation difference of MYL9 in various data sets.
|
Summary | |
---|---|
Symbol | MYL9 |
Name | myosin, light chain 9, regulatory |
Aliases | MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYL9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | MYL9 |
Name | myosin, light chain 9, regulatory |
Aliases | MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYL9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYL9. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | MYL9 |
Name | myosin, light chain 9, regulatory |
Aliases | MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYL9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | MYL9 |
Name | myosin, light chain 9, regulatory |
Aliases | MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of MYL9 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | MYL9 |
Name | myosin, light chain 9, regulatory |
Aliases | MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between MYL9 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | MYL9 |
Name | myosin, light chain 9, regulatory |
Aliases | MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ...... |
Chromosomal Location | 20q11.23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting MYL9 collected from DrugBank database. |
There is no record. |